Amgen Inc.: Beat — EPS $6.45, Revenue $10.4B
Earnings BeatQ3 2026 · After-market
Did Amgen Inc. (AMGN) beat earnings today?
Yes, Amgen Inc. (AMGN) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+11.59% surprise
$6.45Actual
Expected: $5.78
vs. year ago +14.0%
Total Revenue+3.38% surprise
$10.4BActual
Expected: $10.06B
vs. year ago +8.0%
Released Nov 03 · 4:01 PM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $10.40B | - | 8.0% |
| Revenue detail — reported lines | |||
| └─Product sales | $9.88B | $9.14B | 8.0% |
| └─Repatha | $1.08B | $794.00M | 37.0% |
| └─EVENITY | $751.00M | $541.00M | 39.0% |
| └─Prolia | $632.00M | $1.14B | -45.0% |
| └─TEPEZZA | $526.00M | $560.00M | -6.0% |
| └─KRYSTEXXA | $419.00M | $320.00M | 30.9% |
| └─UPLIZNA | $451.00M | $155.00M | 191.0% |
| └─TAVNEOS | $105.00M | $107.00M | -2.0% |
| └─Ultra-Rare products | $110.00M | $200.00M | -45.0% |
| └─TEZSPIRE | $538.00M | $377.00M | 43.0% |
| └─Otezla | $481.00M | $585.00M | -18.0% |
| └─Enbrel | $611.00M | $580.00M | 5.0% |
| └─AMJEVITA/AMGEVITA | $191.00M | $154.00M | 24.0% |
| └─PAVBLU | $300.00M | $213.00M | 41.0% |
| └─WEZLANA/WEZENLA | $260.00M | $44.00M | 490.9% |
| └─BLINCYTO | $496.00M | $392.00M | 27.0% |
| └─IMDELLTRA/IMDYLLTRA | $406.00M | $178.00M | 128.1% |
| └─Vectibix | $335.00M | $284.00M | 18.0% |
| └─KYPROLIS | $330.00M | $359.00M | -8.0% |
| └─LUMAKRAS/LUMYKRAS | $102.00M | $96.00M | 6.0% |
| └─Nplate | $472.00M | $457.00M | 3.0% |
| └─XGEVA | $288.00M | $539.00M | -47.0% |
| └─MVASI | $168.00M | $213.00M | -21.0% |
| └─Aranesp | $329.00M | $357.00M | -8.0% |
| └─Neulasta | $95.00M | $92.00M | 3.3% |
| └─Parsabiv | $84.00M | $86.00M | -2.0% |
| └─Other products | $420.00M | $317.00M | 32.0% |
| GAAP EPS | $7.08 | $5.93 | 19.0% |
| Non-GAAP EPS | $6.45 | $5.64 | 14.0% |
Financial Outlook / Guidance
| Metric | FY26 Outlook | |
|---|---|---|
| Guidance | Expected | |
| Total revenues | $38.9B-$39.7B | $38.97BIn-Line |
| GAAP EPS | $18.34-$19.28 | — |
| Non-GAAP EPS | $22.90-$23.70 | $23.02In-Line |
| Capital expenditures | ~$2.6B | — |
| Share repurchases | ≤$3.0B | — |
FY26 Outlook
- Total revenues
- Guidance$38.9B-$39.7BExpected$38.97BIn-Line
- GAAP EPS
- Guidance$18.34-$19.28Expected—
- Non-GAAP EPS
- Guidance$22.90-$23.70Expected$23.02In-Line
- Capital expenditures
- Guidance~$2.6BExpected—
- Share repurchases
- Guidance≤$3.0BExpected—
Business Highlights
- ➤MariTide MARITIME-CV and both MARITIME-OSA studies completed enrollment.
- ➤MariTide MARITIME-T2D-3 initiated and is enrolling adults with Type 2 diabetes.
- ➤UPLIZNA MERCURY and MOMENT studies were initiated in autoimmune hepatitis and primary membranous nephropathy.
- ➤Dazodalibep Phase 3 OASIZ-301 achieved statistically significant improvements in Sjögren’s disease activity.
- ➤TEZSPIRE Phase 3 CROSSING results showed histologic remission in eosinophilic esophagitis.
- ➤Daxdilimab Phase 2 data supported steps to advance the program to Phase 3.
- ➤FDA reduced IMDELLTRA first-two-dose monitoring from 22-24 hours to 6-8 hours.
- ➤IMDELLTRA DeLLphi-305 showed improved overall and progression-free survival in first-line maintenance.
- ➤FDA accepted the ABP 206 biosimilar BLA for review.
- ➤Paid a $2.52 per-share dividend, a 6% increase from the prior-year period.
Management Commentary
Robert A. Bradway, chairman and chief executive officer
“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise. The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade.”